New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:34 EDTNBYNovaBay announces completion of enrollment in Phase 2 BAYnovation trial
NovaBay announced it has completed enrollment of patients in its global Phase 2b viral conjunctivitis trial, BAYnovation. The trial is investigating NovaBay’s Auriclosene -- NVC-422 -- Ophthalmic Solution as a treatment for adenoviral conjunctivitis, a highly contagious, potentially sight-impairing form of “pink eye”. This condition affects millions of people globally and there is currently no approved treatment available anywhere in the world. NovaBay expects to report results from its trial in mid-2014. BAYnovation is a multi-centered, randomized clinical study that has enrolled patients with adenoviral conjunctivitis in the United States, India, Sri Lanka, and Brazil. Patients were enrolled into the study by 54 clinical investigators, including 18 in the US, 19 in India, 6 in Sri Lanka and 11 in Brazil. BAYnovation was designed to evaluate the efficacy of NovaBay’s Auriclosene Ophthalmic Solution in the treatment of adenoviral infection, specifically clearing the associated red eye and reducing lingering effects left by the infection.
News For NBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 8, 2014
07:06 EDTNBYNovaBay signs exclusive distribution agreement with Biopharm Group
NovaBay Pharmaceuticals announced that it has signed an exclusive distribution agreement for NovaBay’s NeutroPhase Skin and Wound Cleanser with the Biopharm Group, a leading pharmaceutical company in the Middle East, headquartered in Cairo, Egypt. Under the terms of the agreement, Biopharm will market NeutroPhase in Egypt, Saudi Arabia, Algeria, Sudan and Libya.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use